ArticleEmerging microbes & infections2022
A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates.
Open access · goldAbstract read
In one paragraph
Article in Emerging microbes & infections, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 93 citations in OpenAlex.
- Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults.The New England journal of medicine · 2022Trial
- Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.The Lancet. Infectious diseases · 2021Trial
- Receptor binding domain-independent pancoronavirus vaccine design by fusion of conserved T/B Epitopes.Emerging microbes & infections · 2026Article
- Exposure route, not dose, is the primary driver of infection patterns for a respiratory virus.Science advances · 2026Article
- Targeted FcRn to deliver epitope-optimized RBD confers broad-spectrum mucosal protection against SARS-CoV-2.Molecular therapy. Nucleic acids · 2026Article
- The first key for the Priority Pathogens: Protective immunogens in development of vaccines and medications.Biosafety and health · 2026Review
- Exposure route drives SARS-CoV-2 infection patterns in non-human primates.bioRxiv : the preprint server for biology · 2026Article
- Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies.Microbiology and molecular biology reviews : MMBR · 2025Review
- XBB.1.5 RBD-Based Bivalent Vaccines Induced Antibody Responses Against SARS-CoV-2 Variants in Mice.Vaccines · 2025Article
- Boosting with Omicron-specific mRNA vaccine or historical SARS-CoV-2 vaccines elicits discriminating immune responses against Omicron variants.Acta pharmaceutica Sinica. B · 2025Article
- Adjuvant combination and antigen multimerization shape neutralizing antibody and T cell responses to a SARS-CoV-2 RBD subunit vaccine.Frontiers in immunology · 2025Article
- Repeated-dose toxicity and immunogenicity evaluation of a recombinant subunit COVID-19 vaccine (ZF2001) in rats.Frontiers in cellular and infection microbiology · 2025Article
- Clinical characteristics and risk factors for ZF2001 fully vaccinated inpatients with COVID-19: A retrospective cohort study.Human vaccines & immunotherapeutics · 2024Article
- Development of Glycan-masked SARS-CoV-2 RBD vaccines against SARS-related coronaviruses.PLoS pathogens · 2024Article
- Article
- An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza.NPJ vaccines · 2024Article
- Article
- The CDE region of feline Calicivirus VP1 protein is a potential candidate subunit vaccine.BMC veterinary research · 2024Article
- Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.Journal of virology · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 7 institutions in 5 countries.
Yaling AnSavaid Medical School, University of Chinese Academy of Sciences, Beijing, 101408, People's Republic of China.
Shihua LiCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, People's Republic of China.
Xiyue JinSchool of Life Sciences, University of Science and Technology of China, Hefei, Anhui, 230026, People's Republic of China.
Jian-Bao HanKunming National High-Level Biosafety Research Center for Non-human Primates, Center for Biosafety Mega-Science, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650107, People's Republic of China.
Kun XuKey Laboratory of Tropical Translational Medicine of Ministry of Education, School of Tropical Medicine and Laboratory Medicine, The First Affiliated Hospital, Hainan Medical University, Hainan, 571199, People's Republic of China.ORCID 0000-0002-9762-5001
Senyu XuResearch Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, 100101, People's Republic of China.
Yuxuan HanSavaid Medical School, University of Chinese Academy of Sciences, Beijing, 101408, People's Republic of China.
Chuanyu LiuLaboratory of Animal Infectious Diseases, College of Animal Sciences and Veterinary Medicine, Guangxi University, Nanning, 530000, People's Republic of China.
Tianyi ZhengResearch Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, 100101, People's Republic of China.
Mei LiuCAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, People's Republic of China.
Mi YangCAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, People's Republic of China.
Tian-Zhang SongKey Laboratory of Animal Models and Human Disease Mechanism of the Chinese Academy of Sciences, Kunming Institute of Zoology, Chinese Academic of Sciences, Kunming, 650223, People's Republic of China.
Baoying HuangNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.
Li ZhaoNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.
Wen WangNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.
Ruhan ANHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.
Yingjie ChengAnhui Zhifei Longcom Biopharmaceutical Co. Ltd, Anhui, 230088, People's Republic of China.
Changwei WuAnhui Zhifei Longcom Biopharmaceutical Co. Ltd, Anhui, 230088, People's Republic of China.
Enqi HuangAnhui Zhifei Longcom Biopharmaceutical Co. Ltd, Anhui, 230088, People's Republic of China.
Shilong YangAnhui Zhifei Longcom Biopharmaceutical Co. Ltd, Anhui, 230088, People's Republic of China.
Gary WongCAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, People's Republic of China.
Yuhai BiCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, People's Republic of China.ORCID 0000-0002-5595-363X
Changwen KeGuangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, People's Republic of China.
Wenjie TanNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.
Jinghua YanCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, People's Republic of China.ORCID 0000-0003-0502-3829
Yong-Tang ZhengKunming National High-Level Biosafety Research Center for Non-human Primates, Center for Biosafety Mega-Science, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650107, People's Republic of China.
Lianpan DaiSavaid Medical School, University of Chinese Academy of Sciences, Beijing, 101408, People's Republic of China.ORCID 0000-0001-8352-1327
George F GaoSavaid Medical School, University of Chinese Academy of Sciences, Beijing, 101408, People's Republic of China.ORCID 0000-0002-3869-615X
Chinese Academy of Sciences · CNTaiwan Centers for Disease Control · TWBiocom · USKunming Institute of Zoology · CNGuangdong Provincial Center for Disease Control and Prevention · CNGuangxi University · CNUniversity of Science and Technology of China · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Safe, efficacious, and deployable vaccines are urgently needed to control COVID-19 in the large-scale vaccination campaigns. We report here the preclinical studies of an approved protein subunit vaccine against COVID-19, ZF2001, which contains tandem-repeat dimeric receptor-binding domain (RBD) protein with alum-based adjuvant. We assessed vaccine immunogenicity and efficacy in both mice and non-human primates (NHPs). ZF2001 induced high levels of RBD-binding and SARS-CoV-2 neutralizing antibody in both mice and non-human primates, and elicited balanced T
Indexed as
COVID-19COVID-19 VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralCarrier ProteinsHumansImmunogenicity, VaccineMiceMice, Inbred BALB CPrimatesSARS-CoV-2Spike Glycoprotein, CoronavirusVaccines, SubunitAntibodies, NeutralizingAntibodies, ViralCarrier ProteinsCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, SubunitantibodyCovid-19immune responsesubunit protein vaccinezf2001
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.